Axitinib-induced reversible posterior leukoencephalopathy syndrome in a patient with metastatic renal cell carcinoma

A 61-year-old woman with metastatic renal carcinoma was treated with axitinib as a second-line tyrosine kinase inhibitor. Thirteen days after the treatment, the patient developed reversible posterior leukoencephalopathy syndrome (RPLS). Her symptoms and imaging findings resolved after withdrawal of...

Full description

Saved in:
Bibliographic Details
Published inInternational cancer conference journal Vol. 6; no. 4; pp. 197 - 199
Main Authors Nakamura, Kogenta, Saiki, Hiroshi, Muramatsu, Hiroyuki, Morinaga, Shingo, Kobayashi, Ikuo, Kajikawa, Keishi, Nishikawa, Genya, Kato, Yoshiharu, Watanabe, Masahito, Kanao, Kent, Sumitomo, Makoto
Format Journal Article
LanguageEnglish
Published Tokyo Springer Japan 01.10.2017
Springer Nature B.V
Subjects
Blood pressure
Case Report
Case reports
Edema
Etiracetam
Intensive care
Kidney cancer
Leukoencephalopathy
Lungs
Magnetic resonance imaging
Medicine
Medicine & Public Health
Metastases
Metastasis
Oncology
Renal cell carcinoma
Surgical Oncology
Vascular endothelial growth factor
Renal cell carcinoma
Axitinib
Reversible posterior leukoencephalopathy syndrome
Online AccessGet full text

Cover

More Information
Summary:A 61-year-old woman with metastatic renal carcinoma was treated with axitinib as a second-line tyrosine kinase inhibitor. Thirteen days after the treatment, the patient developed reversible posterior leukoencephalopathy syndrome (RPLS). Her symptoms and imaging findings resolved after withdrawal of axitinib, blood pressure control, and administration of glycerin and levetiracetam. RPLS should be kept in mind as a possible rare adverse event after axitinib administration.
ISSN:2192-3183
2192-3183
DOI:10.1007/s13691-017-0306-x